See the DrugPatentWatch profile for cosentyx

There is currently no scientific evidence to suggest that the COVID-19 vaccine immunity is influenced by Cosentyx (secukinumab), an interleukin-17A inhibitor used to treat various immune-mediated diseases such as psoriasis, psoriatic arthritis, and ankylosing spondylitis [1].

Cosentyx works by blocking the action of interleukin-17A, a protein involved in inflammation and the immune response [2]. On the other hand, COVID-19 vaccines stimulate the immune system to produce an immune response against the SARS-CoV-2 virus [3].

While both Cosentyx and COVID-19 vaccines affect the immune system, they target different pathways and mechanisms. Therefore, it is unlikely that Cosentyx would have a significant impact on the immunity generated by COVID-19 vaccines [1].

However, it is essential to note that further research is needed to confirm the potential interactions between Cosentyx and COVID-19 vaccines [1]. Patients taking Cosentyx or other immunosuppressive medications should consult their healthcare providers for personalized advice on COVID-19 vaccination [3].

Sources:

[1] DrugPatentWatch.com. (2021). Cosentyx (secukinumab) COVID-19 Drug Interactions. Retrieved from <https://www.drugpatentwatch.com/drugs/cosentyx-secukinumab/covid-19-drug-interactions/>

[2] Novartis. (2021). Cosentyx (secukinumab) [Prescribing Information]. Retrieved from <https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/cosentyx.pdf>

[3] Centers for Disease Control and Prevention. (2021). People with Certain Medical Conditions. Retrieved from <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/pregnancy.html>